Editorial: Fighting Prescription Drug Abuse with Demonstrated Abuse-Deterrent Formulations

AbuseDeterrent_Article_PA.pngAs published in Pharma's Almanac Q3 2017.

As the number of opioid prescriptions in the US has climbed dramatically, so has the abuse and misuse of these drugs, leading to loss of life and significant social costs. The pharmaceutical industry, in conjunction with FDA, has focused on identifying approaches for the development of abuse-deterrent opioid formulations and methods for demonstrating their effectiveness. Choosing the right strategy for a given drug can be difficult. Partnering with a contract development and manufacturing organization (CDMO) that has experience with different abuse-deterrent opioid formulation methods and established expertise in the development of in vitro abuse-deterrent studies can accelerate approval.

Download Article Here

Topics: Thought Leadership Abuse-Deterrence Editorials